novo nordisk weight loss

Novo Nordisk Shares Fall

Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study

Key Takeaways Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema.The average weight loss among those taking the new drug was 15.

Reuters · 8h

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

CNBC on MSN · 11h

Novo Nordisk shares fall 5.4% after latest trial results for its next-generation weight loss drug

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

US FDA to hold off action on weight-loss drug copies pending court ruling

The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...

8hon MSN

Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

11h

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...

Novo Nordisk to sell Wegovy for $499 a month to cash-paying US customers

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results